Mouse Anti-FH Recombinant Antibody (CBT536) (V2LY-0625-LY3437)

Name: Mouse Anti-FH Recombinant Antibody (CBT536)
SKU: V2LY-0625-LY3437
Rating: 5 (1 reviews)

See all FH antibodies

Compare Online Inquiry

Tested Data

Mouse Anti-FH Recombinant Antibody (CBT536) (V2LY-0625-LY3437) in WB

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBT536

Application

WB, IF, ICC

Immunogen

Recombinant Protein of FH Fumarase

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG

Clonality

Monoclonal Antibody

Application Notes

Application	Note
WB	1:1,000-1:2,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, Glycerol, BSA

Preservative

Sodium azide

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Fumarate Hydratase

Entrez Gene ID

2271

UniProt ID

P07954

Alternative Names

Fumarate Hydratase; EC 4.2.1.2; Fumarase; Fumarate Hydratase, Mitochondrial; HLRCC; MCUL1; FMRD; LRCC; MCL;

Function

Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759).

Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable).

Isoform Mitochondrial:
Catalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH.

Isoform Cytoplasmic:
Catalyzes the dehydration of L-malate to fumarate (By similarity).

Fumarate metabolism in the cytosol plays a role during urea cycle and arginine metabolism; fumarate being a by-product of the urea cycle and amino-acid catabolism (By similarity).

Also plays a role in DNA repair by promoting non-homologous end-joining (NHEJ) (PubMed:20231875, PubMed:26237645).

In response to DNA damage and phosphorylation by PRKDC, translocates to the nucleus and accumulates at DNA double-strand breaks (DSBs): acts by catalyzing formation of fumarate, an inhibitor of KDM2B histone demethylase activity, resulting in enhanced dimethylation of histone H3 'Lys-36' (H3K36me2) (PubMed:26237645).

Biological Process

Cellular response to DNA damage stimulus Source: UniProtKB
DNA repair Source: UniProtKB-KW
Fumarate metabolic process Source: UniProtKB
Homeostasis of number of cells within a tissue Source: Ensembl
Malate metabolic process Source: UniProtKB
Negative regulation of histone H3-K36 methylation Source: UniProtKB
Positive regulation of cold-induced thermogenesis Source: YuBioLab
Positive regulation of double-strand break repair via nonhomologous end joining Source: UniProtKB
Regulation of arginine metabolic process Source: UniProtKB
Tricarboxylic acid cycle Source: GO_Central
Urea cycle Source: UniProtKB

Cellular Location

Isoform Mitochondrial: Mitochondrion
Isoform Cytoplasmic: Cytosol; Nucleus; Chromosome. Translocates to the nucleus in response to DNA damage: localizes to DNA double-strand breaks (DSBs) following phosphorylation by PRKDC.

Involvement in disease

Fumarase deficiency (FMRD):
A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy.
Hereditary leiomyomatosis and renal cell cancer (HLRCC):
Isoform Cytoplasmic:
The disease is caused by variants affecting the gene represented in this entry. Isoform Cytoplasmic: HLRCC is probably caused by an accumulation of fumarate (PubMed:30718813). Accumulation of fumarate coupled with protonation promotes the formation of non-enzymatic post-translational modification cysteine S-succination (S-(2-succinyl)cysteine) on proteins, such as SMARCC1 (PubMed:30718813). A disorder characterized by predisposition to cutaneous and uterine leiomyomas, and papillary type 2 renal cancer which occurs in about 20% of patients.

PTM

Isoform Cytoplasmic:
Phosphorylation at Thr-236 by PRKDC in response to DNA damage promotes translocation to the nucleus and recruitment to DNA double-strand breaks (DSBs).

Hamza, A., Sirohi, D., Smith, S. C., & Amin, M. B. (2021). Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: an update on biologic potential, morphologic spectrum, and differential diagnosis with other low-grade oncocytic tumors. Advances in Anatomic Pathology, 28(6), 396-407.

Sun, G., Zhang, X., Liang, J., Pan, X., Zhu, S., Liu, Z., ... & Zeng, H. (2021). Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell CarcinomaGenomic and Epigenomic Profiling of FH-deficient RCC. Clinical Cancer Research, 27(6), 1734-1743.

Gleeson, J. P., Nikolovski, I., Dinatale, R., Zucker, M., Knezevic, A., Patil, S., ... & Carlo, M. I. (2021). Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell CarcinomaMolecular Analysis and Therapy Response in FH-Deficient RCC. Clinical Cancer Research, 27(10), 2910-2919.

Schmidt, C., Sciacovelli, M., & Frezza, C. (2020, February). Fumarate hydratase in cancer: A multifaceted tumour suppressor. In Seminars in cell & developmental biology (Vol. 98, pp. 15-25). Academic Press.

Kancherla, P., Daneshvar, M., Sager, R. A., Mollapour, M., & Bratslavsky, G. (2020). Fumarate hydratase as a therapeutic target in renal cancer. Expert Opinion on Therapeutic Targets, 24(9), 923-936.

Zhang, L., Walsh, M. F., Jairam, S., Mandelker, D., Zhong, Y., Kemel, Y., ... & Offit, K. (2020). Fumarate hydratase FH c. 1431_1433dupAAA (p. Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human mutation, 41(1), 103-109.

Lau, H. D., Chan, E., Fan, A. C., Kunder, C. A., Williamson, S. R., Zhou, M., ... & Kao, C. S. (2020). A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. The American Journal of Surgical Pathology, 44(1), 98-110.

Wyvekens, N., Valtcheva, N., Mischo, A., Helmchen, B., Hermanns, T., Choschzick, M., ... & Rupp, N. J. (2020). Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Genes, Chromosomes and Cancer, 59(11), 611-619.

Gupta, S., Swanson, A. A., Chen, Y. B., Lopez, T., Milosevic, D., Kipp, B. R., ... & Jimenez, R. E. (2019). Incidence of succinate dehydrogenase and fumarate hydratase–deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Human pathology, 91, 114-122.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-FH Recombinant Antibody (CBT536)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-FH Recombinant Antibody (CBXF-1883) (CAT#: CBMAB-F3416-CQ)

Mouse Anti-FH Recombinant Antibody (CBXF-3006) (CAT#: CBMAB-F3712-CQ)

Mouse Anti-FH Recombinant Antibody (2L3) (CAT#: CBMAB-AP2279LY)

Mouse Anti-FH Recombinant Antibody (CAP799) (CAT#: CBMAB-AP2406LY)

Mouse Anti-FH Recombinant Antibody (AT3F6) (CAT#: CBMAB-F2916-CQ)

Mouse Anti-FH Recombinant Antibody (5H2) (CAT#: CBMAB-AP2278LY)

Mouse Anti-FH Recombinant Antibody (CB214) (CAT#: CBMAB-CS214LY)

Rabbit Anti-FH Recombinant Antibody (CBXF-2063) (CAT#: CBMAB-F2052-CQ)

Mouse Anti-FH Recombinant Antibody (5D4) (CAT#: CBMAB-A2971-LY)

Mouse Anti-FH (AA 452-555) Recombinant Antibody (CBXF-3007) (CAT#: CBMAB-F3713-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry